Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 2:37 AM
Ignite Modification Date:
2025-12-25 @ 2:37 AM
NCT ID:
NCT00858234
Eligibility Criteria:
Inclusion Criteria:
* is ≥20 years of age.
* has an established diagnosis of MM based on the myeloma diagnostic criteria
* has received at least 1 but not more than 3 prior anti-myeloma regimens and has progressive disease after the most recent treatment regimen
* has adequate organ function
Exclusion Criteria:
* has had a prior allogeneic bone marrow transplant or plans to undergo any type of bone marrow transplantation during the study
* has known hypersensitivity to any components of vorinostat or bortezomib
* has active hepatitis B or C, plasma cell leukemia, or is human immunodeficiency virus (HIV) positive
* has had prior treatment with vorinostat or histone deacetylase (HDAC) inhibitors
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
20 Years
Study:
NCT00858234
Study Brief:
Protocol Section:
NCT00858234